Eton Pharmaceuticals, Inc.
ETON
$30.53
$0.581.94%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 40.41% | 82.72% | 117.54% | 108.60% | 116.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.41% | 82.72% | 117.54% | 108.60% | 116.95% |
| Cost of Revenue | 28.43% | 30.73% | 230.18% | 68.13% | 150.79% |
| Gross Profit | 49.43% | 124.23% | 45.65% | 133.40% | 96.94% |
| SG&A Expenses | 13.91% | 31.29% | 53.29% | 73.26% | 77.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.10% | 58.59% | 129.22% | 59.85% | 102.51% |
| Operating Income | 613.62% | 327.78% | -107.66% | 90.87% | 41.25% |
| Income Before Tax | 205.07% | 376.71% | -490.22% | 15.67% | -84.71% |
| Income Tax Expenses | -72.97% | -179.31% | 77.78% | 22.22% | -- |
| Earnings from Continuing Operations | 198.85% | 347.99% | -407.34% | 15.00% | -93.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 198.85% | 347.99% | -407.34% | 15.00% | -93.83% |
| EBIT | 613.62% | 327.78% | -107.66% | 90.87% | 41.25% |
| EBITDA | 552.85% | 291.92% | 23.25% | 127.75% | 195.94% |
| EPS Basic | 197.44% | 340.61% | -396.28% | 18.56% | -85.71% |
| Normalized Basic EPS | 203.74% | 3,547.83% | -221.49% | 57.87% | -76.65% |
| EPS Diluted | 183.33% | 282.37% | -458.50% | 16.67% | -90.48% |
| Normalized Diluted EPS | 189.66% | 3,069.57% | -224.58% | 57.87% | -76.65% |
| Average Basic Shares Outstanding | 1.48% | 3.06% | 3.83% | 4.33% | 4.36% |
| Average Diluted Shares Outstanding | 17.34% | 19.54% | 1.29% | 4.33% | 4.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |